MedTrace Logo

Intravenous Immunoglobulin for Unverricht-Lundborg Disease.

NCT03351569 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2017-11-27

No results posted yet for this study

Summary

Single patient randomized double blind trial to assess whether intravenous immunoglobulin can improve the clinical outcome of a case suffering from Unverricht-Lundborg disease.

Conditions

  • Unverricht-Lundborg Disease

Interventions

DRUG

Intravenous immunoglobulin

Intravenous drip.

Sponsors & Collaborators

  • Azienda Socio Sanitaria Territoriale di Mantova

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
25 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-09
Primary Completion
2016-12-06
Completion
2017-12-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03351569 on ClinicalTrials.gov